11th World Affordable Medicine Congress

11th World Affordable Medicine Congress 7 - 8 February 2017, Barcelona, Spain.
The Annual World Affordable Medicine Congress comes to Barcelona, this is the newly rebranded World Generic Medicines Congress and Biosimilar Drug Development World. For 11 years, the biggest and best in the industry. Through a series of interactives presentation, speed networking and stream sessions, the congress will provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Don't miss out the opportunity to share your experience and network with senior and board level executives working in generic and biosimilar organisations.

Don't miss your chance to hear from:

  • Klaus Martin, Chief Scientific Officer, Polpharma Biologics
  • Matthew Turner, Global Medical Director Biosimilars, Merck
  • Bernd Liedert, Sr.Clinical Program Leader Biosimilars, Boehringer Ingelheim
  • Isabel Afonso, Head of Global Commercial Strategy and member of the Sandoz Executive Committee, Sandoz
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency
  • Adrian Thomas, Vice President of Health Economics & Market Access, Janssen North America

Download the brochure now to see who's speaking.

World Pharma News readers can benefit from an exclusive 10% discount. Quote discount code CGNN

For further information, please visit:
http://www.healthnetworkcommunications.com/conference/affordable-medicines/

About World Affordable Medicine Congress
The World Affordable Medicine Congress Europe brings together two world class events - World Generic Medicines Congress and Biosimilar Drug Development World - that have been central to the industry’s business and networking needs for over 10 years. Over 2000 business leaders participants have benefited from this series since 2007.

The event unites senior executives from the generic and biosimilar industry to provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Most Popular Now

Novartis confirms 5 year data for first and only f…

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension stud...

FDA approves Rituxan Hycela (rituximab and hyaluro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcuta...

Merck Foundation established

Merck, a leading science and technology company, today announced the establishment of the Merck Foundation. Through this foundation Merck combines many of its corporate r...

Researchers develop microneedle patch for flu vacc…

A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce rob...

Novartis Phase III study shows ACZ885 (canakinumab…

Novartis today announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination...

Jardiance® (empagliflozin) analysis reinforces est…

An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (...

Alzheimer's and Parkinson's spurred by same enzyme

Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors. But at ...

Does the emperor have clothes?

Discovered more than two decades ago, the hormone leptin has been widely hailed as the key regulator of leanness. Yet, the pivotal experiments that probe the function of ...

Researchers publish new findings on influence of h…

Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known. In a newly published study, Cleveland Cli...

Merck awards €1.25 million to research projects th…

Merck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the adva...

Trials show unique stem cells a potential asthma t…

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma. The Mo...

FDA tackles drug competition to improve patient ac…

Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]